Vanguards of Healthcare: SR One’s George on Next Biotech Cycle
“I think this is an incredible time to be investing in biotech,” says Dr. Simeon George, founder and CEO of SR One, who joins Bloomberg Intelligence analyst Sam Fazeli to...
By Mariam Traore · Bloomberg
“I think this is an incredible time to be investing in biotech,” says Dr. Simeon George, founder and CEO of SR One, who joins Bloomberg Intelligence analyst Sam Fazeli to discuss why biotech’s next cycle will be global, selective and unforgiving. George traces SR One’s evolution from one of pharma’s oldest corporate venture arms to an independent firm with more than $2 billion raised. The conversation explores why AI’s real test is cutting development time and attrition, not just discovering tar